Evidence map›Paper›PMID 31667678›Full record

Trial reportAIDS and behavior2020

Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.

Sarah T Roberts, Gonasagrie Nair, Jared M Baeten, Thesla Palanee-Philips, Katie Schwartz, Krishnaveni Reddy, Samuel Kabwigu, Flavia Matovu Kiweewa, Vaneshree Govender, Zakir Gaffoor and 5 more

Open access · greenAbstract readClinical Trial, Phase III
In one paragraph

Trial report in AIDS and behavior, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. "Frontiers in reproductive health · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Sarah T RobertsWomen's Global Health Imperative, RTI International, 351 California Street, Ste. 500, San Francisco, CA, 94104, USA. sroberts@rti.org.ORCID http://orcid.org/0000-0002-3318-9781
Gonasagrie NairDesmond Tutu HIV Research Centre, University of Cape Town, Cape Town, South Africa.
Jared M BaetenDepartments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA, USA.
Thesla Palanee-PhilipsWits Reproductive Health and HIV Institute (Wits RHI), Johannesburg, South Africa.
Katie SchwartzFHI 360, Durham, NC, USA.
Krishnaveni ReddyWits Reproductive Health and HIV Institute (Wits RHI), Johannesburg, South Africa.
Samuel KabwiguMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Flavia Matovu KiweewaMakerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Vaneshree GovenderHIV Prevention Research Unit (HPRU), Medical Research Council (MRC), Durban, South Africa.
Zakir GaffoorHIV Prevention Research Unit (HPRU), Medical Research Council (MRC), Durban, South Africa.
Nishanta SinghHIV Prevention Research Unit (HPRU), Medical Research Council (MRC), Durban, South Africa.
Samantha SivaHIV Prevention Research Unit (HPRU), Medical Research Council (MRC), Durban, South Africa.
Kalendri NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Elizabeth T MontgomeryWomen's Global Health Imperative, RTI International, 351 California Street, Ste. 500, San Francisco, CA, 94104, USA.
for the MTN-020/ASPIRE Team
South African Medical Research Council · ZARTI International · USDesmond Tutu HIV Foundation · ZAFamily Health International 360 · USMUJHU Research Collaboration · UGUniversity of Washington · US

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
South African Medical Research Council Clinical Trials Unit (MRC CTU)UM1AI069422 · NIAID · MEDICAL RESEARCH COUNCIL OF SOUTH AFRICA · PI ABDULLAH, MAHOMED FAREED ABOOBAKER, GOGA, AMEENA · 2012 to 2020
$37.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
National Institute of Allergy and Infectious Diseases UM1AI068615National Institute of Allergy and Infectious Diseases UM1AI068633National Institute of Allergy and Infectious Diseases UM1AI106707NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068633NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069422NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

Although vaginal microbicides for HIV prevention are designed to be female-initiated, male partner influence has been identified as one of the most significant factors impacting women's willingness and ability to use them. As a result, research teams have sought to increase male partner involvement by encouraging disclosure of product use to male partners, promoting male partner engagement in the study through attendance at the study clinic, and helping women to garner male partner support for product use. This paper aims to assess the impact of these three elements of male partner involvement on women's adherence to the dapivirine vaginal ring during MTN-020/ASPIRE, a phase III randomized placebo-controlled clinical trial involving 2629 women in Malawi, South Africa, Uganda, and Zimbabwe. During the study, 64-80% of participants reported disclosure of ring use at each quarterly visit, and 13% reported that their partners had attended the study clinic at some point during the study. At study exit, 66% reported that their partner was supportive, 18% unsupportive, and 17% were unsure. After adjusting for age, site and time in study, women were more likely to have low ring adherence if they had an unsupportive male partner (aRR 1.29, 95% CI 1.03-1.62). Neither disclosure nor clinic attendance directly predicted ring adherence, but disclosure increased the probability of having a supportive partner (aRRR 24.17, 95% CI 16.38-35.66) or an unsupportive partner (aRRR 4.10, 95% CI 2.70-6.24), relative to an unknown level of partner support. Women were also more likely to have a supportive partner if their partner had attended the clinic (aRRR 3.77, 95% CI 1.36-10.42). This study suggests that although the vaginal ring is relatively discreet, lack of support from male partners remains a relevant barrier to use. Though both disclosure and clinic attendance may increase partner support, disclosure may also increase partner opposition. Interventions to reduce male partner opposition are needed to maximize the potential impact of the ring and other PrEP products for HIV prevention.

Indexed as

Contraceptive Devices, FemaleHIV InfectionsAdolescentAdultAnti-HIV AgentsFemaleHumansMalawiMalePyrimidinesSouth AfricaUgandaYoung AdultZimbabweAnti-HIV AgentsDapivirinePyrimidinesDapivirine vaginal ringGenderHIV preventionMale involvementMicrobicidesWomen

Identifiers

PMID31667678
PMCPMC7162727
OpenAlexW2982390122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.